The dynamics of the pancreatic endocrine tumor market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the disease, incremental healthcare spending worldwide, and the expected launch of emerging therapies.
LAS VEGAS, Aug. 3, 2023 /PRNewswire/ -- DelveInsight's Pancreatic Endocrine Tumor Market Insights report includes a comprehensive understanding of current treatment practices, pancreatic endocrine tumor emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Pancreatic Endocrine Tumor Market Report
- As per DelveInsight analysis, the pancreatic endocrine tumor market is expected to grow positively at a significant CAGR during the study period (2019–2032).
- Pancreatic neuroendocrine tumours are rare. Pancreatic NETs account for less than 2% of all cancers detected in the pancreas each year. The number of pancreatic NETs detected each year has been increasing over time.
- Leading pancreatic endocrine tumor companies such as Merck Sharp & Dohme LLC, Viewpoint Molecular Targeting, Eli Lilly and Company, RayzeBio, Inc., Endeavor Biomedicines, Inc., ProDa BioTech, LLC, Helix BioPharma Corporation, Theradex, SynerGene Therapeutics, Inc., Mirati Therapeutics Inc., Novartis, Syntrix Biosystems, Inc., Lantheus Medical Imaging, HCW Biologics, SOFIE, Eli Lilly and Company, Boehringer Ingelheim, Targovax ASA, Cantex Pharmaceuticals, XBiotech, Inc., CARsgen Therapeutics Co., Ltd., Biomea Fusion Inc., and others are developing novel pancreatic endocrine tumor drugs that can be available in the pancreatic endocrine tumor market in the coming years.
- Some key therapies for pancreatic endocrine tumor treatment include Belzutifan, [212Pb]VMT-α-NET, Abemaciclib, RYZ101, ENV-101 (taladegib), ProAgio, L-DOS47 + Doxorubicin, SGT-53, MRTX849, FOLFIRINOX + NIS793, SX-682, Piflufolastat F18, HCW9218, [68Ga]FAPI-46, LY3214996, Nintedanib, TG01 Vaccine, Azeliragon, XB2001, CT041, BMF-219, and others.
Discover which therapies are expected to grab the major pancreatic endocrine tumor market share @ Pancreatic Endocrine Tumor Market Report
Pancreatic Endocrine Tumor Overview
Pancreatic endocrine tumors (PETs) are a rare type of neoplasms that arise from the hormone-producing cells within the pancreas, known as the islet cells. These tumors can be benign or malignant and can release a variety of hormones, leading to distinct clinical manifestations. While the exact cause of PETs remains largely unknown, certain risk factors may increase the likelihood of their development. The causes of pancreatic endocrine tumors are not fully understood, but some factors might contribute to their formation. Genetic predisposition and hereditary conditions, such as multiple endocrine neoplasia type 1 (MEN1) and Von Hippel-Lindau syndrome, are known to increase the risk of PETs.
The symptoms of PETs can vary depending on the hormones they secrete. Insulinomas, which release excess insulin, can cause hypoglycemia, leading to symptoms like weakness, confusion, and dizziness. Glucagonomas may result in hyperglycemia (high blood sugar), leading to frequent urination, excessive thirst, and weight loss. Other types of PETs can produce hormones like gastrin, somatostatin, or vasoactive intestinal peptide, leading to various digestive disturbances and systemic effects. Diagnosing pancreatic endocrine tumors can be challenging due to their rarity and diverse clinical presentations. Medical professionals may use a combination of imaging techniques, such as CT scans, MRI, and endoscopic ultrasound, to locate and characterize the tumor.
Pancreatic Endocrine Tumor Epidemiology Segmentation
The pancreatic endocrine tumor epidemiology section provides insights into the historical and current pancreatic endocrine tumor patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
The disease epidemiology covered in the report provides historical as well as forecasted pancreatic endocrine tumor epidemiology scenarios in the 7MM covering the United States, EU4 countries (Germany, Spain, Italy, France), the United Kingdom, and Japan from 2019 to 2032.
Pancreatic Endocrine Tumor Treatment Market
The pancreatic endocrine tumor treatment depends on various factors such as the tumor size, location, grade, and the extent of its spread. The mainstay of pancreatic endocrine tumor treatment for localized or small PETs is surgical resection, which involves removing the tumor and surrounding tissue. In cases where the tumor cannot be surgically removed, other pancreatic endocrine tumor treatment options come into play.
For advanced or metastatic PETs, therapeutic approaches may include medical pancreatic endocrine tumor treatments such as somatostatin analogs, targeted therapies, and peptide receptor radionuclide therapy (PRRT). Somatostatin analogs help in controlling hormonal symptoms by inhibiting hormone release from the tumor. Targeted therapies aim at blocking specific pathways that promote tumor growth. PRRT involves administering radioactive substances that selectively target the tumor cells.
In some cases, combination therapy using a mix of treatments may be utilized to maximize effectiveness. The management of pancreatic endocrine tumors often requires a multidisciplinary approach involving endocrinologists, oncologists, surgeons, and radiologists, ensuring personalized treatment plans tailored to the patient's specific needs. Early detection and timely intervention play a vital role in improving outcomes and enhancing the quality of life for individuals affected by pancreatic endocrine tumors.
To know more about pancreatic endocrine tumor treatment, visit @ Pancreatic Endocrine Tumor Treatment Drugs
Key Pancreatic Endocrine Tumor Therapies and Companies
- Belzutifan: Merck Sharp & Dohme LLC
- [212Pb]VMT-α-NET: Viewpoint Molecular Targeting
- Abemaciclib: Eli Lilly and Company
- RYZ101: RayzeBio, Inc.
- ENV-101 (taladegib): Endeavor Biomedicines, Inc.
- ProAgio: ProDa BioTech, LLC
- L-DOS47 + Doxorubicin: Helix BioPharma Corporation/Theradex
- SGT-53: SynerGene Therapeutics, Inc.
- MRTX849: Mirati Therapeutics Inc.
- FOLFIRINOX + NIS793: Novartis
- SX-682: Syntrix Biosystems, Inc.
- Piflufolastat F18: Lantheus Medical Imaging
- HCW9218: HCW Biologics
- [68Ga]FAPI-46: SOFIE
- LY3214996: Eli Lilly and Company
- Nintedanib: Boehringer Ingelheim
- TG01 Vaccine: Targovax ASA
- Azeliragon: Cantex Pharmaceuticals
- XB2001: XBiotech, Inc.
- CT041: CARsgen Therapeutics Co., Ltd.
- BMF-219: Biomea Fusion Inc.
Learn more about the FDA-approved drugs for pancreatic endocrine tumor @ Drugs for Pancreatic Endocrine Tumor Treatment
Pancreatic Endocrine Tumor Market Dynamics
The pancreatic endocrine tumor market has witnessed significant dynamics in recent years, driven by various factors that have shaped its growth and development. One of the primary drivers is the increasing prevalence of pancreatic endocrine tumors, leading to a rise in the demand for effective diagnostic and treatment options. Additionally, advancements in medical technology and diagnostic tools have improved early detection rates, thereby positively impacting the pancreatic endocrine tumor market's growth.
Moreover, the growing awareness among healthcare professionals and patients regarding the importance of timely diagnosis and treatment has also played a crucial role in propelling pancreatic endocrine tumor market expansion. As a result, pharmaceutical companies and research institutions have intensified their efforts to develop innovative therapeutic approaches, including targeted therapies and personalized medicine, to cater to the specific needs of patients with pancreatic endocrine tumors.
However, the pancreatic endocrine tumor market dynamics are not without challenges. Limited access to healthcare facilities and high treatment costs in certain regions may hinder the pancreatic endocrine tumor market's growth potential. Additionally, the complexity of pancreatic endocrine tumors and the variability in patient responses to treatments pose significant obstacles in achieving successful outcomes.
Nonetheless, the rising investments in research and development, coupled with collaborations between industry players and academic institutions, are expected to drive advancements in treatment options and pave the way for a more promising future for patients with pancreatic endocrine tumors. As the understanding of the disease and its underlying mechanisms improves, there is a growing hope for more effective, targeted therapies and personalized treatment approaches, which will undoubtedly shape the dynamics of the pancreatic endocrine tumor market in the coming years.
Report Metrics | Details |
Study Period | 2019–2032 |
Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
Key Pancreatic Endocrine Tumor Companies | Merck Sharp & Dohme LLC, Viewpoint Molecular Targeting, Eli Lilly and Company, RayzeBio, Inc., Endeavor Biomedicines, Inc., ProDa BioTech, LLC, Helix BioPharma Corporation, Theradex, SynerGene Therapeutics, Inc., Mirati Therapeutics Inc., Novartis, Syntrix Biosystems, Inc., Lantheus Medical Imaging, HCW Biologics, SOFIE, Eli Lilly and Company, Boehringer Ingelheim, Targovax ASA, Cantex Pharmaceuticals, XBiotech, Inc., CARsgen Therapeutics Co., Ltd., Biomea Fusion Inc., and others |
Key Pancreatic Endocrine Tumor Therapies | Belzutifan, [212Pb]VMT-α-NET, Abemaciclib, RYZ101, ENV-101 (taladegib), ProAgio, L-DOS47 + Doxorubicin, SGT-53, MRTX849, FOLFIRINOX + NIS793, SX-682, Piflufolastat F18, HCW9218, [68Ga]FAPI-46, LY3214996, Nintedanib, TG01 Vaccine, Azeliragon, XB2001, CT041, BMF-219, and others |
Scope of the Pancreatic Endocrine Tumor Market Report
- Therapeutic Assessment: Pancreatic Endocrine Tumor current marketed and emerging therapies
- Pancreatic Endocrine Tumor Market Dynamics: Conjoint Analysis of Emerging Pancreatic Endocrine Tumor Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL's views, Analyst's views, Pancreatic Endocrine Tumor Market Access and Reimbursement
Discover more about pancreatic endocrine tumor drugs in development @ Pancreatic Endocrine Tumor Clinical Trials
Table of Contents
1. | Pancreatic Endocrine Tumor Market Key Insights |
2. | Pancreatic Endocrine Tumor Market Report Introduction |
3. | Pancreatic Endocrine Tumor Market Overview at a Glance |
4. | Pancreatic Endocrine Tumor Market Executive Summary |
5. | Disease Background and Overview |
6. | Pancreatic Endocrine Tumor Treatment and Management |
7. | Pancreatic Endocrine Tumor Epidemiology and Patient Population |
8. | Patient Journey |
9. | Pancreatic Endocrine Tumor Marketed Drugs |
10. | Pancreatic Endocrine Tumor Emerging Drugs |
11. | Seven Major Pancreatic Endocrine Tumor Market Analysis |
12. | Pancreatic Endocrine Tumor Market Outlook |
13. | Potential of Current and Emerging Therapies |
14. | KOL Views |
15. | Unmet Needs |
16. | SWOT Analysis |
17. | Appendix |
18. | DelveInsight Capabilities |
19. | Disclaimer |
20. | About DelveInsight |
Related Reports
Pancreatic Endocrine Tumor Pipeline
Pancreatic Endocrine Tumor Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key pancreatic endocrine tumor companies, including MedPacto, AstraZeneca, Helsinn, QED Therapeutics, Inovio Pharmaceuticals, Abbisko Therapeutics, Bayer, 4D pharma plc, RemeGen, Infinity Pharmaceuticals, Kyowa Kirin, Inc., Ikena Oncology, Vyriad, Seagen, RemeGen, Pfizer, Incyte Corporation, Prestige BioPharma, TARIS Biomedical, Janssen Research and Development, among others.
Pancreatic Cancer Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key pancreatic cancer companies, including AstraZeneca, Merck Sharp & Dohme LLC, Bayer, Roche, Celgene, Bristol Myers Squibb, BioLineRx, Alligator Bioscience, Bellicum Pharmaceuticals, OSE Immunotherapeutics, Actuate Therapeutics, FibroGen, NeoImmuneTech, NOXXON Pharma, Silenseed Ltd., Amgen, NGM Biopharmaceuticals, Merus, Mirati Therapeutics, Rexahn Pharmaceuticals, Ocuphire Pharma, Processa Pharmaceuticals, ImmunityBio, Berg, Panbela Therapeutics, GlaxoSmithKline, Eleison Pharmaceuticals, Molecular Templates, Lokon Pharma AB, Cantargia AB, among others.
Pancreatic Cancer Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key pancreatic cancer companies, including FibroGen, Innovent Biologics, CARsgen Therapeutics, Ascentage Pharma, NGM Biopharmaceuticals, TME Pharma AG, Lee's Pharmaceutical Limited, ImmunityBio, Inc., Rgene Corporation, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., CanBas Co. Ltd., Jiangsu HengRui Medicine Co., Ltd., Bristol-Myers Squibb, SynerGene Therapeutics, Inc., AbbVie, Silenseed Ltd, Galera Therapeutics, Inc., Helix BioPharma, Golden Biotechnology Corporation, Eli Lilly and Company, Innovent Biologics (Suzhou) Co. Ltd., Panbela Therapeutics, Inc., GlaxoSmithKline, Chia Tai Tianqing Pharmaceutical Group, Roche, Prestige Biopharma Limited, Everfront Biotech Co., Ltd., XBiotech, Inc., Incyte Corporation, Ability Pharmaceuticals SL, Lokon Pharma, HCW Biologics, Amplia Therapeutics Limited, BioLineRx, Ltd., Taiho Pharmaceutical, Sanofi, Scandion Oncology, Nelum, Celldex Therapeutics, Merus N.V., Seagen Inc., GC Cell Corporation, MetiMedi Pharmaceuticals, Lumicell, Nuvation Bio Inc., ENB Therapeutics, BioNTech SE, Bayer, Genentech, Inc., Rise Biopharmaceuticals, Inc., Prestige Biopharma Limited, iOnctura, Shanghai Unicar-Therapy Bio-medicine Technology, Shanghai Hengrui Pharmaceutical Co., Ltd., Hangzhou Neoantigen Therapeutics Co., Ltd., EUSA Pharma, Inc.,Agenus Inc., Arcus Biosciences, Inc.Amgen, Biomea Fusion, among others.
Gastroenteropancreatic Neuroendocrine Tumors Market
Gastroenteropancreatic Neuroendocrine Tumors Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key gastroenteropancreatic neuroendocrine tumors companies, including Novartis, Ipsen Biopharmaceuticals, Pfizer, ITM Isotopen Technologien Muenchen, Camurus AB, Hutchison Medipharma Limited, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:
Voltar noticias em Inglês